CovidChloroV1, Main, Exploration, bibRecord, 000849

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.

Identifieur interne : 000849 ( Main/Exploration ); précédent : 000848; suivant : 000850

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.

Auteurs : Awadhesh Kumar Singh [Inde] ; Akriti Singh [Inde] ; Altamash Shaikh [Inde] ; Ritu Singh [Inde] ; Anoop Misra [Inde]

Source :

Diabetes & metabolic syndrome [ 1878-0334 ]

RBID : pubmed:32247211

Descripteurs français

KwdFr :
- Betacoronavirus (effets des médicaments et des substances chimiques), Chloroquine (usage thérapeutique), Complications du diabète (MeSH), Diabète (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Inde (MeSH), Infections à coronavirus (complications), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pays en voie de développement (MeSH), Pneumopathie virale (complications), Pneumopathie virale (traitement médicamenteux).
MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Chloroquine, Hydroxychloroquine, Infections à coronavirus, Pneumopathie virale.
- Complications du diabète, Diabète, Humains, Inde, Pandémies, Pays en voie de développement.
Wicri :
- geographic : Inde.

English descriptors

KwdEn :
- Betacoronavirus (drug effects), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Developing Countries (MeSH), Diabetes Complications (MeSH), Diabetes Mellitus (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), India (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
MESH :
- chemical , therapeutic use : Chloroquine, Hydroxychloroquine.
- geographic : India.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Developing Countries, Diabetes Complications, Diabetes Mellitus, Humans, Pandemics, SARS-CoV-2.

Abstract

BACKGROUND AND AIMS

No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.

AIMS AND METHODS

We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19.

RESULTS

Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.

CONCLUSION

Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown.

DOI: 10.1016/j.dsx.2020.03.011
PubMed: 32247211
PubMed Central: PMC7102587

Affiliations:

Inde

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001A32
to stream Main, to step Curation: 001A32

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.</title>
<author><name sortKey="Singh, Awadhesh Kumar" sort="Singh, Awadhesh Kumar" uniqKey="Singh A" first="Awadhesh Kumar" last="Singh">Awadhesh Kumar Singh</name>
<affiliation wicri:level="1"><nlm:affiliation>G. D Hospital & Diabetes Institute, Kolkata, India. Electronic address: draksingh_2001@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>G. D Hospital & Diabetes Institute, Kolkata</wicri:regionArea>
<wicri:noRegion>Kolkata</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Singh, Akriti" sort="Singh, Akriti" uniqKey="Singh A" first="Akriti" last="Singh">Akriti Singh</name>
<affiliation wicri:level="1"><nlm:affiliation>College of Medicine & JNM Hospital, Kalyani, Nadia, West Bengal, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>College of Medicine & JNM Hospital, Kalyani, Nadia, West Bengal</wicri:regionArea>
<wicri:noRegion>West Bengal</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shaikh, Altamash" sort="Shaikh, Altamash" uniqKey="Shaikh A" first="Altamash" last="Shaikh">Altamash Shaikh</name>
<affiliation wicri:level="1"><nlm:affiliation>Saifee Hospital, Mumbai, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Saifee Hospital, Mumbai</wicri:regionArea>
<wicri:noRegion>Mumbai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Singh, Ritu" sort="Singh, Ritu" uniqKey="Singh R" first="Ritu" last="Singh">Ritu Singh</name>
<affiliation wicri:level="1"><nlm:affiliation>G. D Hospital & Diabetes Institute, Kolkata, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>G. D Hospital & Diabetes Institute, Kolkata</wicri:regionArea>
<wicri:noRegion>Kolkata</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Misra, Anoop" sort="Misra, Anoop" uniqKey="Misra A" first="Anoop" last="Misra">Anoop Misra</name>
<affiliation wicri:level="1"><nlm:affiliation>Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi</wicri:regionArea>
<wicri:noRegion>New Delhi</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 May - Jun</date>
<idno type="RBID">pubmed:32247211</idno>
<idno type="pmid">32247211</idno>
<idno type="doi">10.1016/j.dsx.2020.03.011</idno>
<idno type="pmc">PMC7102587</idno>
<idno type="wicri:Area/Main/Corpus">001A32</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A32</idno>
<idno type="wicri:Area/Main/Curation">001A32</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A32</idno>
<idno type="wicri:Area/Main/Exploration">001A32</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.</title>
<author><name sortKey="Singh, Awadhesh Kumar" sort="Singh, Awadhesh Kumar" uniqKey="Singh A" first="Awadhesh Kumar" last="Singh">Awadhesh Kumar Singh</name>
<affiliation wicri:level="1"><nlm:affiliation>G. D Hospital & Diabetes Institute, Kolkata, India. Electronic address: draksingh_2001@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>G. D Hospital & Diabetes Institute, Kolkata</wicri:regionArea>
<wicri:noRegion>Kolkata</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Singh, Akriti" sort="Singh, Akriti" uniqKey="Singh A" first="Akriti" last="Singh">Akriti Singh</name>
<affiliation wicri:level="1"><nlm:affiliation>College of Medicine & JNM Hospital, Kalyani, Nadia, West Bengal, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>College of Medicine & JNM Hospital, Kalyani, Nadia, West Bengal</wicri:regionArea>
<wicri:noRegion>West Bengal</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shaikh, Altamash" sort="Shaikh, Altamash" uniqKey="Shaikh A" first="Altamash" last="Shaikh">Altamash Shaikh</name>
<affiliation wicri:level="1"><nlm:affiliation>Saifee Hospital, Mumbai, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Saifee Hospital, Mumbai</wicri:regionArea>
<wicri:noRegion>Mumbai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Singh, Ritu" sort="Singh, Ritu" uniqKey="Singh R" first="Ritu" last="Singh">Ritu Singh</name>
<affiliation wicri:level="1"><nlm:affiliation>G. D Hospital & Diabetes Institute, Kolkata, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>G. D Hospital & Diabetes Institute, Kolkata</wicri:regionArea>
<wicri:noRegion>Kolkata</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Misra, Anoop" sort="Misra, Anoop" uniqKey="Misra A" first="Anoop" last="Misra">Anoop Misra</name>
<affiliation wicri:level="1"><nlm:affiliation>Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi</wicri:regionArea>
<wicri:noRegion>New Delhi</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetes & metabolic syndrome</title>
<idno type="eISSN">1878-0334</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (drug effects)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Developing Countries (MeSH)</term>
<term>Diabetes Complications (MeSH)</term>
<term>Diabetes Mellitus (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>India (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Complications du diabète (MeSH)</term>
<term>Diabète (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Inde (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Pays en voie de développement (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Developing Countries</term>
<term>Diabetes Complications</term>
<term>Diabetes Mellitus</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Complications du diabète</term>
<term>Diabète</term>
<term>Humains</term>
<term>Inde</term>
<term>Pandémies</term>
<term>Pays en voie de développement</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND AIMS</b>
</p>
<p>No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>AIMS AND METHODS</b>
</p>
<p>We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32247211</PMID>
<DateCompleted><Year>2020</Year>
<Month>04</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0334</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>3</Issue>
<PubDate><MedlineDate>2020 May - Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Diabetes & metabolic syndrome</Title>
<ISOAbbreviation>Diabetes Metab Syndr</ISOAbbreviation>
</Journal>
<ArticleTitle>Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.</ArticleTitle>
<Pagination><MedlinePgn>241-246</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1871-4021(20)30051-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dsx.2020.03.011</ELocationID>
<Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.</AbstractText>
<AbstractText Label="AIMS AND METHODS" NlmCategory="OBJECTIVE">We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown.</AbstractText>
<CopyrightInformation>Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Awadhesh Kumar</ForeName>
<Initials>AK</Initials>
<AffiliationInfo><Affiliation>G. D Hospital & Diabetes Institute, Kolkata, India. Electronic address: draksingh_2001@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Akriti</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>College of Medicine & JNM Hospital, Kalyani, Nadia, West Bengal, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shaikh</LastName>
<ForeName>Altamash</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Saifee Hospital, Mumbai, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Ritu</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>G. D Hospital & Diabetes Institute, Kolkata, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Misra</LastName>
<ForeName>Anoop</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Diabetes Metab Syndr</MedlineTA>
<NlmUniqueID>101462250</NlmUniqueID>
<ISSNLinking>1871-4021</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Chloroquine</Keyword>
<Keyword MajorTopicYN="N">Diabetes</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
</KeywordList>
<CoiStatement>Declaration of competing interest We hereby declare that we have no conflict of interest related to this article.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32247211</ArticleId>
<ArticleId IdType="pii">S1871-4021(20)30051-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.dsx.2020.03.011</ArticleId>
<ArticleId IdType="pmc">PMC7102587</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1990 Aug;34(8):1512-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2221859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20706626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Trop Med Hyg. 1999 Aug;61(2):180-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10463664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2016 Apr 22;291(17):9218-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26953343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2004 Mar;48(3):747-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14982759</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Nov;83(22):11979-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19759137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):404-412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173241</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 May 17;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2007 Sep-Nov;1(5-6):189-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453426</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2016 Dec;88(12):2170-2178</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27183377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):211-212</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32172175</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Des Devel Ther. 2018 Jun 11;12:1685-1695</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29928112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):69-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ophthalmology. 2016 Jun;123(6):1386-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26992838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32070753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2015 Jun;21(6):1065-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25988934</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>HIV Med. 2015 Nov;16(10):585-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26238012</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Inde</li>
</country>
</list>
<tree><country name="Inde"><noRegion><name sortKey="Singh, Awadhesh Kumar" sort="Singh, Awadhesh Kumar" uniqKey="Singh A" first="Awadhesh Kumar" last="Singh">Awadhesh Kumar Singh</name>
</noRegion>
<name sortKey="Misra, Anoop" sort="Misra, Anoop" uniqKey="Misra A" first="Anoop" last="Misra">Anoop Misra</name>
<name sortKey="Shaikh, Altamash" sort="Shaikh, Altamash" uniqKey="Shaikh A" first="Altamash" last="Shaikh">Altamash Shaikh</name>
<name sortKey="Singh, Akriti" sort="Singh, Akriti" uniqKey="Singh A" first="Akriti" last="Singh">Akriti Singh</name>
<name sortKey="Singh, Ritu" sort="Singh, Ritu" uniqKey="Singh R" first="Ritu" last="Singh">Ritu Singh</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000849 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000849 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32247211
   |texte=   Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32247211" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki